Form 4: Harmony Biosciences Director Receives Stock Option Grant

Director Geno J. Germano was granted 21,231 stock options in Harmony Biosciences Holdings, Inc. as part of standard compensation.

Summary

• Director Geno J. Germano received a grant of 21,231 stock options on May 14, 2026.
• The options have an exercise price of $30.76 per share.
• The options are set to expire on May 14, 2036.
• The grant vests in 36 equal monthly installments starting June 14, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in nature.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the granted options.
• Potential for future dilution of equity.

Future Outlook

The options vest over a three-year period, indicating a long-term retention and performance incentive for the director.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure leadership remains incentivized toward long-term growth and stability.

Comparison to Industry Standards

• The use of monthly vesting over 36 months is consistent with standard industry practices for board compensation.
• The grant size is typical for non-executive director compensation packages in mid-cap biotech firms.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options to begin on June 14, 2026.

Key Dates

Keywords

Harmony Biosciences, HRMY, Form 4, Insider Trading, Stock Options, Director Compensation